Solid Bioscience Stock Price, News & Analysis

Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:40 pm ET. The event will be accessible via a live webcast on the company’s website, with a replay available afterward. Solid Biosciences focuses on genetic medicines for neuromuscular and cardiac diseases, highlighting candidates like SGT-003 for Duchenne and AVB-202 for Friedreich’s Ataxia. The company aims to improve patient lives and is committed to advancing its innovative therapies.

The Pathway Development Consortium, co-founded by Solid Biosciences (SLDB), published a peer-reviewed manuscript in Human Gene Therapy, proposing microdystrophin expression levels as a surrogate endpoint for AAV gene therapy in Duchenne muscular dystrophy. This approach could expedite patient access to effective therapies under the FDA's accelerated approval pathway. A white paper submitted to the FDA further supports this initiative, advocating the use of muscle fat fraction and microdystrophin levels as predictive endpoints. These collaborative efforts aim to enhance therapeutic options for patients.

Solid Biosciences (Nasdaq: SLDB) has announced a strategic collaboration with Phlox Therapeutics aimed at addressing severe genetic dilated cardiomyopathy (DCM). This partnership will leverage Solid's vector biology and manufacturing expertise alongside Phlox's RNA therapeutic capabilities to develop innovative gene therapies. The collaboration seeks to meet the significant unmet needs in treating DCM, enhancing both companies' scientific and commercial potential in cardiac therapy.

Solid Biosciences (Nasdaq: SLDB) plans to file an Investigational New Drug (IND) application for SGT-003, a gene therapy for Duchenne muscular dystrophy, in the second half of 2023. The company is also transitioning manufacturing processes for its candidates targeting Friedrich's Ataxia and dilated cardiomyopathy. Kevin Tan has been appointed as Chief Financial Officer. Solid reports approximately $214 million in cash, which is expected to fund strategic priorities into 2025. The company aims to advance its gene therapies, focusing on high unmet needs in neuromuscular and cardiac diseases.

On January 6, 2023, Solid Biosciences Inc. (Nasdaq: SLDB) approved inducement awards for new CFO Kevin Tan. The grant includes an option to purchase 90,000 shares and a restricted stock unit for 45,000 shares, aligning with Nasdaq rules. The options have a ten-year term with an exercise price set at $6.00, the closing stock price on January 9, 2023. The vesting schedule is structured to promote retention, with 25% vested after one year and monthly vesting thereafter for the option, while the restricted stock units will vest over four years.

Solid Biosciences Inc. (Nasdaq: SLDB) has appointed Kevin Tan as Chief Financial Officer. With over 20 years of financial experience, Tan's expertise in capital markets and gene therapy is expected to support the company’s growth and pipeline advancement. CEO Bo Cumbo expressed confidence in Tan’s leadership at this pivotal time for the company. Solid continues to focus on developing genetic medicines for neuromuscular and cardiac diseases, aiming to enhance patient outcomes through innovative treatments.

Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:00 am PT / 12:00 pm ET. Interested institutional investors can schedule meetings with management through their J.P. Morgan representatives. A live webcast of the presentation will be available on the company's website's Events page, with a replay accessible for 30 days. Solid Biosciences focuses on developing genetic medicines for neuromuscular and cardiac diseases, including programs for Duchenne and Friedreich’s Ataxia.

Solid Biosciences (Nasdaq: SLDB) announced inducement awards for its newly appointed executive team, including President and CEO Bo Cumbo and other key officers. The grants were approved by the board under Nasdaq rules, totaling stock options for 192,833 shares and RSUs for 85,514 shares to 22 new hires. Each award vests over four years, with a ten-year term and an exercise price of $6.77 per share, aligned with the company’s stock price at the time of the awards. This announcement coincided with Solid's acquisition of AavantiBio, emphasizing its commitment to advancing therapies for neuromuscular and cardiac diseases.

Solid Biosciences (Nasdaq: SLDB) has completed its acquisition of AavantiBio, a gene therapy company specializing in neuromuscular and cardiac diseases. The merger creates a new precision genetic medicine entity focused on therapies for Duchenne muscular dystrophy, Friedreich’s ataxia, and other cardiac conditions. The combined company holds approximately $215 million in cash and investments, sufficient to fund operations until 2025. Bo Cumbo will lead the merged company as President and CEO, with a focus on advancing key gene therapy programs.